Trials / Recruiting
RecruitingNCT07186296
EXoPERT EMERALD Clinical Study
EXoPERT EMERALD: Early Multi-cancer Study of EV's Ramen-AL Linked Diagnosis Clinical Study Protocol
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,400 (estimated)
- Sponsor
- EXoPERT · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Accepted
Summary
Invitro diagnostic test for multiple cancer diagnosis for patients with early-stage cancers by analyzing surface-enhanced Ramen spectroscopy (SERS) profiles of extracellular vesicles (EV) using artificial intelligence.
Detailed description
An in vitro diagnostic medical device and system that provides information on the presence of lung, ovarian, breast, pancreas and colorectal cancers based on a deep learning analysis for Raman spectroscopic profiles of EV's extracted from human plasma. Tissue of origin (TOO) can be presented as one or more.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | EXoPred | Performing invitro Diagnostics with devices developed by EXoPERT. |
Timeline
- Start date
- 2025-05-09
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2025-09-22
- Last updated
- 2026-01-21
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT07186296. Inclusion in this directory is not an endorsement.